Heat Biologics Культура компании

Ms. Ann A. Rosar, M.B.A., has been Vice President of Finance and Corporate Secretary at Heat Biologics, Inc. since April 05, 2016 and served as its Controller since January 2015. Ms. Rosar is a Partner in StepUP. She has over twenty years of experience in finance with publicly held companies and more than ten years of experience regarding regulatory reporting requirements. Her experience included Manager of Financial Reporting and Accounting, Senior Financial Analyst and Business Manager. Prior to Midatech Pharma US Inc., she served as the Manager of Financial Reporting and Accounting with Cicero, Inc. (formerly Level 8 Systems) from June 2000 to November 2007. Ms. Rosar served as Vice President of Finance at DARA BioSciences, Inc., (now Midatech Pharma US Inc.) since March 2012. She served as Chief Accounting Officer of Midatech Pharma US Inc. from January 9, 2009 to March 2012 and served as its Principal Financial Officer. Ms. Rosar served as Controller of Midatech Pharma US Inc. from November 2007 to January 2009 and served there from 2007 to 2013. She served as Manager of Financial Reporting and Accounting for LipoScience, Inc. specialized cardiovascular diagnostic tests, from 2013 to 2015, where she was responsible for Security Exchange Commission reporting, audits and budget analysis. Prior to Cicero, she served as Senior Financial Analyst of Business Operations for Nextel Communications. Ms. Rosar is active as a volunteer. She has MBA in Finance from University of Houston, where she was a Sigma Iota Epsilon, Beta Gamma Sigma, Phi Kappa Phi and Financial Management Honor Society member. She earned Undergraduate degree from North Carolina State University.

Dr. Jeff T. Hutchins, Ph.D., has been Chief Scientific Officer and Senior Vice President of Pre-Clinical Research, Heat Biologics and Pelican Therapeutics at Heat Biologics, Inc. since July 13, 2017. Dr. Hutchins served as the Chief Scientific and Operating Officer at Heat Biologics, Inc. since July 2017 and served as its Chief Scientific Officer and Senior Vice President of Preclinical Development since January 1, 2017. Dr. Hutchins served as Vice President of Preclinical Research at Peregrine Pharmaceuticals, Inc. from September 2012 to 2016. Dr. Hutchins served as Vice President of Pre-Clinical Development at Inhibitex, Inc., since 2007. He served as Director of Monoclonal Antibody Development from 2001 to 2007. From 1991 to 2000, he held several Senior Scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome with a Visiting Professor appointment in the Department of Biochemistry at Rush Medical College. He has over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies. He publications and patents span the fields of infectious disease, immunology, oncology and osteoarthritis. Dr. Hutchins received a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at Houston ??? Graduate School of Biomedical Sciences, M.D. Anderson Hospital and Cancer Center and Postdoctoral Training from University of Southern California ??? Department of Microbiology.

Dr. Justin Stebbing, M.D., M.A., FRCP, FRC Path, Ph.D., serves as the Chief Medical Advisor of Heat Biologics, Inc. Dr. Stebbing serves as Scientific Advisor at Champions Oncology, Inc. He serves as a Advisor to Lansdowne Partners. He is a leading oncology expert. He serves as a Professor of Cancer Medicine and Oncology\Senior Lecturer at Imperial College and Imperial College Healthcare NHS Trust. He is a Co-Editor-in-Chief of Oncogene. He has extensive biopharma investment experience, served as an Advisor to Atticus Capital. He serves as the Chairman of Bb Healthcare Trust. He served as the Chairman of Member of Clinical Advisory at Heat Biologics, Inc. and serves as its Member of Scientific & Clinical Advisory Board. He serves as a Director of Curemark, LLC. He served as a Member of Scientific Advisory Board at Silence Therapeutics plc and Alivia Swiss Health Management AG. He served as a Member of Scientific Advisory Board and Member of Clinical Advisory Board at Heat Biologics, Inc. He has an extensive clinical practice and links this to a wide number of translational research studies. He serves on the Advisory Boards of a number of international cancer committees. He has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal of Medicine, Blood, PNAS, The Journal of Clinical Oncology and Annals of Internal Medicine, the majority as first or last author, as well as over 100 book chapters, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at major international conferences. He focused at Imperial on new therapies in cancer and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. The charity Action Against Cancer has been set up to support his work which concentrates on drug development and has the ambitious goal of developing cures. After completion of Junior Doctor posts in Oxford, he did a Residency (Junior Doctor) training at The Johns Hopkins Hospital in the US, trained in Oncology at The Royal Marsden and St Bartholomew's Hospital. He is a Member of the Royal College of Physicians, American Board of Internal Medicine and a Fellow of the Royal College of Pathologists. He trained in Medicine at Trinity College Oxford, obtaining a triple first class degree. In 2012 the National Institute for Health Research (NIHR) awarded him for his first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. Dr. Stebbing received his PhD from Imperial College, London, funded by the Medical Research Council, investigating the interplay between the immune system and cancer. He has a Bachelor's Degree from Trinity College, Oxford University in Medicine.

Jeff Hutchins serves as the Chief Scientific and Operations Officer of Heat Biologics. Jeff started at Heat Biologics in July of 2017. Jeff currently resides in Raleigh-Durham, North Carolina Area.

Ann Rosar serves as the Vice President Finance/Controller of Heat Biologics. Ann started at Heat Biologics in January of 2015. Ann currently resides in Raleigh-Durham, North Carolina Area.

Gary Vinson serves as the Vice President, Chemistry & Mfg. Controls of Heat Biologics. Gary started at Heat Biologics in October of 2017. Gary currently resides in Raleigh-Durham, North Carolina Area.

Lori McDermott serves as the Vice President Clinical Development of Heat Biologics. Lori started at Heat Biologics in August of 2017. Lori currently resides in Tampa/St. Petersburg, Florida Area.